Therapeutic Solutions International Inc TSOI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TSOI is a good fit for your portfolio.
News
-
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
-
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
-
Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $2.54 Mil
- Volume/Avg
- 52.4 Mil / 20.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy and traumatic brain injury and Lung Pathology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3
Valuation
|
Metric
|
TSOI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.86 |
Price/Sales | 17.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TSOI
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.05 |
Interest Coverage | −4.25 |
Quick Ratio
TSOI
Profitability
|
Metric
|
TSOI
|
|---|---|
Return on Assets (Normalized) | −59.17% |
Return on Equity (Normalized) | −163.12% |
Return on Invested Capital (Normalized) | −74.42% |
Return on Assets
TSOI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Txttbscx | Jvln | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ynlqzwv | Rfdqw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Snqpgvfdk | Nxhmjf | $97.8 Bil | |
MRNA
| Moderna Inc | Kldnhbh | Ncrbn | $38.8 Bil | |
ARGX
| argenx SE ADR | Vtvrwyzns | Qfc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zhxbbspg | Yxk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zplzghvvj | Qjqnz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ydzxkjprp | Wfyzth | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mmlnvtnr | Xhktf | $12.5 Bil | |
INCY
| Incyte Corp | Fqfcmsbl | Hwxztwy | $11.5 Bil |